Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02039076 · ClinicalTrials.gov registry record · Phase 1

A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects

A Phase 1 study of Thrombocytopenia, sponsored by Eisai.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
1
Study location

NCT02039076: Completed Phase 1 study of Thrombocytopenia, sponsored by Eisai.

NCT02039076 is a Phase 1 study of Thrombocytopenia that has completed, run by Eisai. The registered enrollment target is 48 participants, below the 310-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02039076, a Phase 1 study of Thrombocytopenia, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

This will be a randomized, open-label, 5-treatment-period study to evaluate the PK and PD of avatrombopag following a single administration of avatrombopag in the fed and fasted condition, or the fed condition, to healthy Japanese and white subjects. A standard high-fat, high calorie breakfast will be used to assess the fed condition.

Primary Outcome

The following PK parameters will be estimated for plasma: Cmax, AUC, and t1/2.

Conditions Studied

Interventions

  • DRUG avatrombopag

Study Locations (1)

California

  • Parexel International Early Development Clinical Units - Glendale

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2013-12
Est. Completion 2014-09
Phase Phase 1
Eisai

287 total trials

What the finished NCT02039076 record still lists

NCT02039076 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 310-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which avatrombopag is the first listed.

NCT02039076 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02039076 about?

NCT02039076 is a clinical study titled "A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects". This will be a randomized, open-label, 5-treatment-period study to evaluate the PK and PD of avatrombopag following a single administration of avatrombopag in the fed and fasted condition, or the fed condition, to healthy Japanese and white subjects. A standard high-fat, high calorie breakfast will ...

What is the current status of trial NCT02039076?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-12. Estimated completion is 2014-09.

What conditions does trial NCT02039076 study?

This clinical trial studies the following conditions: Thrombocytopenia.

What interventions are being tested in trial NCT02039076?

The interventions under investigation include: avatrombopag (DRUG).

Who is sponsoring clinical trial NCT02039076?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02039076 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Thrombocytopenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02039076's enrollment target sits among peer trials

48 11th of 20 higher than 10 of 20 other Thrombocytopenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Thrombocytopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02039076, the US trial registry maintained by the National Library of Medicine. NCT02039076 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.